Aurobindo Pharma
Scale generics manufacturer with deep API backward integration, expanding into injectables, biosimilars, and a large Penicillin-G (PLI) backward-integration project.
A full research profile for one company — what it does, how its financials have trended, how the market values it, and a balanced bull/bear/base investment memo.
Scan the top row for the headline numbers, read the charts for trends, check the three gauge scores, then read the auto-generated memo at the bottom. Sources for every figure are linked at the very bottom.
- EBITDA
- — Earnings before interest, tax, depreciation & amortisation — a proxy for operating cash profit.
- PAT
- — Profit After Tax — the bottom-line net profit.
- FCF
- — Free Cash Flow — cash left after running the business and capital spending.
- ANDA
- — Abbreviated New Drug Application — the US FDA filing to sell a generic drug.
Revenue
₹ crore · FY
EBITDA
₹ crore · FY
Margins
EBITDA & PAT margin %
R&D Spend
₹ crore · FY
Free Cash Flow
₹ crore · FY
Revenue Mix
By geography / segment
Quality Score
Growth Score
Regulatory Risk
Snapshot
Business Model
How the company makes money
Large-volume US/EU oral solids & injectables, vertically integrated API, biosimilars & Pen-G capex.
Injectables + biosimilars + Pen-G integration
Low-margin commodity exposure & capex payback
Peer Group
Click to compare
| Peer | Rev CAGR | EBITDA% | ROCE | P/E |
|---|---|---|---|---|
| Aurobindo Pharma | 8% | 20% | 13% | 23x |
| Lupin | 25% | 23% | 30.3% | 18x |
| Zydus Lifesciences | 12% | 30% | 24% | 20x |
| Dr. Reddy's Laboratories | 4% | 26% | 13.6% | 25x |
| Alembic Pharmaceuticals | -5% | 15.2% | 13% | 20x |
Investment Memo
Auto-generated from the data layer — illustrative, not advice
- • Injectables + biosimilars + Pen-G integration underpins a 8% 5Y revenue CAGR.
- • Operating leverage as scale builds toward higher margins (currently 20% EBITDA).
- • Capacity already in place to support the next growth phase.
- • Low-margin commodity exposure & capex payback.
- • ~47% US exposure leaves earnings sensitive to price erosion and FDA action.
- • Re-rating depends on proving R&D/return discipline.
Aurobindo Pharma screens as a improving us generics franchise. With revenue of ₹31.7K Cr growing ~8% and 20% EBITDA margins, the base case is steady compounding driven by injectables + biosimilars + pen-g integration, while watching low-margin commodity exposure & capex payback.
Trades at 23x P/E, 11.0x EV/EBITDA and 2.2x P/B. Reasonable versus growth — re-rating optionality if execution improves.
- 1 USFDA facility status & ANDA approval cadence
- 2 Gross-margin trajectory & new-launch contribution
- 3 R&D productivity (filings/approvals per ₹ of R&D)
- 4 Capital allocation — capex payback & M&A discipline
ANDA cumulative ~830 filed / ~600 approved (company profile, approximate).